Streamlining Gastroenterology Denial Management with Klivira

Klivira's platform provides a robust solution for gastroenterology denial management, automating the complex process of identifying, appealing, and resolving denied prior authorizations and claims.

Revenue cycle teams in gastroenterology practices face a disproportionate burden from prior authorization denials, especially for high-cost biologics, advanced imaging, and complex procedures. Manual denial workflows lead to significant rework, delayed revenue, and potential patient care disruptions. Klivira transforms this challenge into an opportunity for efficiency and financial recovery.

The Unique Landscape of Gastroenterology Denials

Gastroenterology prior authorization frequently involves high-volume, high-value services such as IBD biologics (e.g., Humira, Stelara, Skyrizi, Entyvio), advanced endoscopic procedures (e.g., capsule endoscopy, ERCP), and specialty drugs for functional GI disorders. Denials often stem from specific clinical criteria, step therapy requirements, or documentation gaps unique to GI guidelines (ACG, AGA, AASLD), making effective gastroenterology denial management crucial for financial health.

Common Denial Triggers in GI

Step therapy non-compliance for IBD biologics, including requirements for conventional therapy or TNF inhibitor trials before non-TNF agents.
Payer mandates for biosimilar substitution over brand TNF inhibitors.
Insufficient documentation of disease severity (e.g., missing Mayo score or CDAI) or pre-treatment screenings (TB, hepatitis).
Fibrosis stage documentation gaps for Hepatitis C direct-acting antivirals (DAAs).
Inappropriate-use criteria for advanced imaging like MR enterography, lacking sufficient clinical correlation.
Prior workup insufficient for capsule endoscopy or indication not meeting payer policy.

The Cost of Manual Denial Workflows in GI

Without automation, gastroenterology practices grapple with manual parsing of X12 835 and 277 denial codes, disparate payer portal messages, and labor-intensive appeal letter generation. This leads to high administrative costs, timely-filing breaches, and lost revenue from appeals that are never pursued due to staff capacity constraints, directly impacting the practice's bottom line.

Klivira's Automated Denial Management Workflow for GI

Multi-channel denial ingestion from X12 835/277, Da Vinci PAS `ClaimResponse`, and payer portals.
Automated CARC/RARC normalization into a uniform denial reason taxonomy, specific to GI clinical contexts.
Intelligent auto-routing of GI denials to claim-correction, appeal, or peer-to-peer pathways based on payer-specific policies and normalized reasons.
Automated assembly of appeal packets, pulling relevant clinical documentation (e.g., Mayo score, genotype, fibrosis stage) from the EMR via FHIR.
Proactive tracking of appeal status with timely-filing window enforcement for chronic GI treatments.
Feedback loops that identify denial patterns by specific GI biologic, procedure, or payer to inform upstream PA submission improvements.

Addressing GI-Specific Denial Failure Modes

Klivira specifically addresses gastroenterology denial challenges such as the chronic re-authorization burden for IBD biologics and the variability in biosimilar substitution policies. Our system ensures accurate treatment-naive vs. treatment-experienced classification and facilitates the correct routing for medical vs. pharmacy benefit splits, reducing common points of failure in GI prior authorization and claim processes.

Key Gastroenterology PA Triggers Leading to Denials

Biologics for IBD (e.g., Humira, Stelara, Skyrizi, Entyvio, Remicade, Xeljanz) requiring specific step therapy and documentation of disease activity.
Hepatitis C direct-acting antivirals (e.g., Epclusa, Mavyret) with complex genotype and fibrosis stage criteria.
Advanced imaging like MRCP, MR enterography, and CT enterography, often requiring detailed clinical justification.
Endoscopic procedures such as capsule endoscopy (CPT 91110), ERCP, and EUS, subject to specific medical necessity policies.
Specialty drugs for functional GI disorders (e.g., Viberzi, Motegilide, Linzess, Trulance) often requiring trials of conservative therapies.
Non-routine colonoscopy surveillance (e.g., post-polypectomy) that may trigger PA on some plans.

Frequently asked questions

How does Klivira handle step therapy denials for GI biologics?

Klivira's platform incorporates ACG/AGA-guideline-aware step therapy logic. When a denial occurs due to step therapy non-compliance, the system identifies the specific requirement (e.g., trial of 5-ASA or a TNF inhibitor) and helps assemble an appeal packet with documentation of prior conventional therapy or an appropriate clinical override justification.

Can Klivira help with denials related to biosimilar substitution mandates?

Yes, Klivira's payer-policy logic distinguishes per-payer biosimilar mandates. If a brand TNF inhibitor is denied because a biosimilar is required, the system flags this reason and can guide the appeal process or facilitate a resubmission with the appropriate biosimilar.

How does Klivira ensure timely filing for GI denial appeals?

Klivira enforces per-payer timely-filing windows for all appeals. The system proactively surfaces deadlines and tracks appeal status, providing auto-escalation alerts if an appeal remains unaddressed, preventing lost revenue due to missed submission windows.

What kind of documentation does Klivira pull for GI appeal packets?

For clinical-necessity denials in GI, Klivira leverages FHIR to pull relevant clinical documentation from the EMR. This includes disease severity scores (Mayo score, CDAI), genotype and fibrosis stage for Hep C, prior treatment history, and screening results (TB, hepatitis) to strengthen the appeal packet.

Does Klivira support denials for both medical and pharmacy benefit GI drugs?

Yes, Klivira handles denials for GI biologics administered under both medical and pharmacy benefits. The platform's medical-vs-pharmacy benefit routing ensures that denials for provider-administered infusions and self-administered injections are managed through appropriate channels, even for the same patient or agent over time.

How does Klivira help prevent future GI denials?

Klivira's reporting and pattern detection capabilities analyze denial reasons by payer, specific GI drug, or procedure. This data feeds back into upstream prior authorization submission processes, enabling practices to identify and correct common issues, thereby reducing future denial rates.